FULVESTRANT 250 MG (250 MG / 5 ML) SOLUCIÓN PARA INYECCIÓN EN JERINGA PRELLENADA Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

fulvestrant 250 mg (250 mg / 5 ml) solución para inyección en jeringa prellenada

dr. reddy's laboratories (uk) limited - fulvestrant - fulvestrant....250,00 mg

FULVESTRANT EVER PHARMA 250 MG/5 ML SOLUCIÓN INYECTABLE EN JERINGA PRELLENADA, I.M. Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

fulvestrant ever pharma 250 mg/5 ml solución inyectable en jeringa prellenada, i.m.

ever valinject gmbh - fulvestrant - fulvestrant....50,00 mg

FULVESTRANT 250mg Millilitre Solution for injection in pre-filled syringe Ireland - English - HPRA (Health Products Regulatory Authority)

fulvestrant 250mg millilitre solution for injection in pre-filled syringe

accord healthcare limited - fulvestrant - solution for injection in pre-filled syringe - 250mg millilitre - anti-estrogens

TEVA-FULVESTRANT INJECTION SOLUTION Canada - English - Health Canada

teva-fulvestrant injection solution

teva canada limited - fulvestrant - solution - 50mg - fulvestrant 50mg - antineoplastic agents

APO-FULVESTRANT SOLUTION Canada - English - Health Canada

apo-fulvestrant solution

apotex inc - fulvestrant - solution - 50mg - fulvestrant 50mg - antineoplastic agents

ACT FULVESTRANT SOLUTION Canada - English - Health Canada

act fulvestrant solution

actavis pharma company - fulvestrant - solution - 50mg - fulvestrant 50mg - antineoplastic agents

FULVESTRANT INTAS fulvestrant 250 mg/5 mL solution for injection pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

fulvestrant intas fulvestrant 250 mg/5 ml solution for injection pre-filled syringe

accord healthcare pty ltd - fulvestrant, quantity: 250 mg - injection, solution - excipient ingredients: castor oil; benzyl benzoate; ethanol; benzyl alcohol - fulvestrant intas is indicated for the treatment of postmenopausal women with: ? hormone-receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, locally advanced or metastatic breast cancer who have not been previously treated with endocrine therapy. ? hr positive, locally advanced or metastatic breast cancer who have progressive disease following prior endocrine (anti-oestrogen or aromatase inhibitor) therapy.

FULVESTRANT-TEVA SOLUTION FOR INJECTION 250MG5ML Singapore - English - HSA (Health Sciences Authority)

fulvestrant-teva solution for injection 250mg5ml

teva pharmaceutical investments singapore pte. ltd. - fulvestrant - injection, solution - fulvestrant 250 mg/5ml

FULVESTRANT-AFT SOLUTION FOR INJECTION IN PREFILLED-SYRINGE 250MG5ML Singapore - English - HSA (Health Sciences Authority)

fulvestrant-aft solution for injection in prefilled-syringe 250mg5ml

apex pharma marketing pte. ltd. - fulvestrant - injection, solution - fulvestrant 250mg/5ml

Fulvestrant Sandoz New Zealand - English - Medsafe (Medicines Safety Authority)

fulvestrant sandoz

sandoz new zealand limited - fulvestrant 50 mg/ml;   - solution for injection - 250 mg/5ml - active: fulvestrant 50 mg/ml   excipient: benzyl alcohol benzyl benzoate castor oil ethanol - fulvestrant sandoz is indicated for the treatment of locally advanced or metastatic breast cancer in postmenopausal women of any age previously treated with endocrine therapy (antioestrogen or aromatase inhibitor) therapy, irrespective of whether their postmenopausal status occurred naturally or was artificially induced